DNA - NYSE

Ginkgo Bioworks Holdings, Inc.

DNA·NYSE

$8.73

-6.4%

HealthcareBiotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$570.28M

EPS-5.6400

P/E Ratio-1.55

Earnings Date08/06/2026

dna

Other Current Liabilities

Last Annual Value

66.46M

3-Year CAGR

5-Year CAGR

10%

10-Year CAGR

11%

Adjust for Inflation

Ginkgo Bioworks Holdings, Inc. Competitors Analysis of Other Current Liabilities

DNA · NYSE

Company	Other Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Ginkgo Bioworks Holdings, Inc. NYSE:DNA	66.46M	6.9%	10.5%	N/A
Vir Biotechnology, Inc. NASDAQ:VIR	74.21M	99.5%	N/A	N/A
Replimune Group, Inc. NASDAQ:REPL	6.07M	-22.2%	6.3%	N/A
Arvinas, Inc. NASDAQ:ARVN	40.50M	-5.5%	26.7%	N/A
Iovance Biotherapeutics, Inc. NASDAQ:IOVA	112.16M	48.0%	N/A	46.1%
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	39.48M	-6.1%	15.9%	N/A
Astria Therapeutics, Inc. NASDAQ:ATXS	0.00	N/A	N/A	N/A
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	20.00M	N/A	N/A	N/A
MeiraGTx Holdings plc NASDAQ:MGTX	83.18M	26.3%	69.0%	45.5%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	12.35M	108.4%	N/A	N/A

Ginkgo Bioworks Holdings, Inc. Fair Value Envelope

DNA · NYSE

Our analysis suggests that DNA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.73, this represents a potential HIDDEN relative to our calculated worth for Ginkgo Bioworks Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $8.73

Related Guides

Blog Categories

Continue your DNA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.